A liquid biopsy for cancer screening looks for traces of tumour DNA in a blood sample. Multi-cancer early detection (MCED) tests analyse methylation patterns on cell-free DNA to flag a possible cancer signal and suggest where in the body it may come from. The best-studied test is Galleri.

What the studies show

In the CCGA validation study (2,823 people with cancer, 1,254 without), specificity was 99.5%, so about 1 in 200 people without cancer received a false signal. Sensitivity was 51.5% overall and rose with stage: 16.8% for stage I, 40.4% stage II, 77.0% stage III and 90.1% stage IV [Klein 2021]. Early cancers, the ones screening most wants to find, are therefore often missed.

In the PATHFINDER study of people without known cancer, 35 of those with a cancer signal were diagnosed with cancer, and most of these were types without a recommended screening test [GRAIL/PATHFINDER].

The first randomised trial, NHS-Galleri, followed about 142,000 adults aged 50 to 77 in England. Results presented in 2026 showed that it did not meet its primary endpoint of reducing combined stage III and IV diagnoses. Secondary analyses found fewer stage IV cancers in the second and third screening rounds and more cancers found through screening [QMUL; LabMedica]. Whether this reduces cancer deaths is not yet known.

What this means for you

A negative result does not rule out cancer, and a positive result needs imaging and further tests. Liquid biopsy can add to, but not replace, recommended screening such as colorectal, breast and cervical screening. For tumour markers in a standard blood test, see what cancer markers can and cannot tell you.

Liquid biopsy at Aeonix

Aeonix is preparing to offer liquid biopsy as an optional add-on through laboratory partners, alongside the annual biomarker plans. Availability, pricing and partner details will be published on this page. Results are validated and physician reviewed by the partner laboratory. Aeonix does not make a diagnosis; discuss abnormal values with your doctor.

Frequently asked questions

Can a blood test detect cancer early?

Multi-cancer tests can detect a cancer signal, but in the CCGA study only about 17% of stage I cancers were detected. A negative result does not rule out cancer.

Did the NHS-Galleri trial show a benefit?

It did not meet its primary endpoint of fewer stage III and IV diagnoses. Secondary results showed fewer stage IV cancers in later screening rounds; effects on deaths are not yet known.

Does liquid biopsy replace standard screening?

No. It may add to guideline-recommended screening but does not replace it.

Sources

Aeonix: Own Your Health

Up to 150+ clinically validated biomarkers. Physician-reviewed results in 48–72 hours. Renowned Swiss lab. GDPR-compliant.

Join Waitlist Now